Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients
暂无分享,去创建一个
T. Habuchi | M. Miura | S. Satoh | H. Kagaya | Toshio Suzuki | H. Tada | Yorihisa Tanaka | Yoshihiko Itoh | Y. Tanaka | K. Inoue
[1] T. Habuchi,et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[2] M. Miura. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[3] N. Yasui-Furukori,et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. , 2005, British journal of clinical pharmacology.
[4] T. Habuchi,et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.
[5] T. Habuchi,et al. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[6] A. Munakata,et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. , 2005, British journal of clinical pharmacology.
[7] D. Holt,et al. Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians , 2005, Transplantation.
[8] T. Habuchi,et al. Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.
[9] M. Miura,et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.
[10] M. Miura,et al. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] P. Beaune,et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] J. Chun,et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[13] W. Weimar,et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.
[14] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[15] Ji-Young Park,et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 , 2002, Clinical pharmacology and therapeutics.
[16] E. Schuetz,et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.
[17] J. Azuma,et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.
[18] K. Ohashi,et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night‐time in different CYP2C19 genotype groups , 2002, Alimentary pharmacology & therapeutics.
[19] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[20] M. Haberl,et al. The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.
[21] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[22] S. Ishihara,et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.
[23] J. Witte,et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.
[24] S. Yamaguchi,et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.
[25] T. Suzuki,et al. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.
[26] C. Nakamura,et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.
[27] A. D. Rodrigues,et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.
[28] U. Christians,et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[29] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[30] D. Dunn,et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.
[31] H. Satoh,et al. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.